Three gene therapy pioneers just won the Breakthrough Prize. This is their story

Ryan Cross / endpoints - A trio of scientists behind the first gene therapy approved in the United States have been awarded a Breakthrough Prize in Life Sciences. It’s arguably one of the most prominent recognitions yet for the field ...

AI Summary: Three gene‑therapy researchers received the Breakthrough Prize in recognition of foundational work that enabled the first CRISPR-based sickle cell therapy. The award highlights decades of basic and translational research that turned genome editing from lab curiosity into a tangible clinical remedy, with winners sharing a multimillion‑dollar prize and public acclaim.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #researchfunding #clinicaltrials

4 months / medicalxpress

4 months / bbc

4 months / livescience


Back to Top / Sat, April 18, 2026, 8:21 pm / permalink 22421 / 9 stories in 4 months /




Related Stories


Analysis finds anti-amyloid Alzheimer's drugs lack meaningful benefit / 4 months

Prediction markets wager on drug trials, raising research integrity concerns / 4 wks

The peptide problem: Hype outruns evidence, researchers caution / 3 months

Fecal capsule transplant reduces peanut allergy in early human and mouse studies / 24 days

Mid‑stage Parkinson trial failure halts drug development plans / 3 months

FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 3 months

Antiviral ensitrelvir dramatically cuts household COVID transmission risk / 3 months

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Vaccine Safety, Digital Health, Neuroscience, Reproductive Health and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.